436 results about "Meglumine" patented technology

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.

The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component.

The ginkgo leaf powder for injection contains ginkgo extractive 1 weight portions, hydroxypropy1 betacyclodextrin 1-4 weight portions and pH regulator meglumine or sodium bicarbonate 0.02-0.08 weight portions. The preparation process includes mixing ginkgo extractive, hydroxypropy1 betacyclodextrin and pH regulator; filtering and ultrafiltering with 50000-150000 dalton ultrafiltering film; and direct bacteria-free freeze drying or spray drying of the ultrafiltered liquid to obtain the powder for injection. The said preparation process of the present invention can maintain fully the effective components while eliminating macro molecules, pyretogen, particle, microbe and other impurities to raise the safety and stability of the preparation obviously.

The present invention discloses one kind of bilobalide powder for injection and features its composition including bilobalide, meglumine and hydroxypropyl-beta-cyclodextrin in the weight ratio of 1 to 0.2-0.5 to 6-9. The present invention also discloses the preparation process of the bilobalide powder for injection. The bilobalide powder for injection has supplementary material capable of dissolving bilobalide completely without destroying its structure, and bilobalide as the main material is slightly soluble in water and easily soluble in acetone. The key point of the present invention is to select hydroxypropyl-beta-cyclodextrin as the solubilkizing supplementary material to raise the solubility of bilobalide greatly, and this raises the bioavailability of bilobalide and the curative effect of the injection greatly.

This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

Lansoprazole is a second generation proton pump inhibitor developed by Takeda in Japan, and is clinically and widely applied for treatment of acid related diseases and helicobacter pylori eradiation. The invention provides a preparation method of a Lansoprazole lyophilized powder injection preparation, creatively screens and tests the composition and dosage as well as the technology of the Lansoprazole lyophilized powder injection, obtains the optimal experiment condition, and gains good effect. The weight ratio of all the components of the Lansoprazole lyophilized powder injection satisfies the relation that Lansoprazole: meglumine: mannitol: sodium hydroxide equals to 30:10:60:4-4.1, the optimal weight ratio of all the components meets the relation that Lansoprazole: meglumine: mannitol: sodium hydroxide equals to 30:10:60:4.

The invention relates to a pharmaceutical composition containing high concentration of polydatin and process for preparation, wherein the composition comprises polydatin, meglumine and / or cyclodextrin, and other pharmaceutically acceptable auxiliary materials and carriers. The composition can be polydatin aqueous solution, or the lyophilized product prepared into aqueous solution before use. In the aqueous solution, the concentration of polydatin is not lower than 5mg/ml.

The freeze dried Lansoprazole sodium sdinjection has Lansoprazole sodium as active component and mannitol or meglumine as excipient in the weight ratio of 15-30 g to 5-50 g. The preparation process of the freeze dried Lansoprazole sodium injection includes the following steps: dissolving Lansoprazole sodium in 15-30 g in injection water of 200-400 ml, dissolving mannitol or meglumine as excipient in 5-50 g in injection water of 100-300 ml, mixing the two kinds of obtained solutions and adding injection water to 2000-3000 ml, adding active carbon in 0.5-1.5 g, filtering with microporous filter membrane, packing in vial, freeze drying under bacteria-free condition, and pressing cap. The freeze dried Lansoprazole sodium injection is used clinically in intravenous drip or intramuscular injection to treat peptic ulcer and other diseases.

The invention belongs to the technical field of medicinal preparation, and in particular relates to a telmisartan tablet composition. The telmisartan tablet composition is characterized by being prepared from 80 parts of telmisartan, 6.72 parts of sodium hydroxide, 24 parts of meglumine, 250 to 280 parts of sorbierite, 58 to 88 parts of calcium hydrophosphate, 20 parts of polyvidone and 10 parts of magnesium stearate. By selecting and using the combination of sorbierite and calcium hydrophosphate as filler, the composition can obviously improve the stability of the preparation and is favorable for production and application of the preparation.

The invention relates to a derivative of an aza-aryl compound as shown in the formula I, and the derivative is capable of adjusting erythropoietin (EPO). The derivative comprises the sodium salt, meglumine salt, hydrobromic acid and hydrochloride of the aza-aryl compound as shown in the formula I, and is high in solubility and water stability in an aqueous medium. In addition, the inventor discovers that the derivative is effective for treating cancers and related anemia.

The invention relates to a silybin injection and its preparation method, which comprises silybin meglumine, glucosamine, alkaline amino acid solubiliser and pharmaceutically acceptable solvent, or compound of silybin and alkaline solubiliser and pharmaceutically acceptable solvent, the pH is 4-11. The injection also comprises one or more of pharmaceutically acceptable solubilizer, pH regulator, isotonic conditioning agent, painkiller, anti-oxidant agent, preservative and complexing agent.

The invention relates to a rosuvastatin calcium oral drug composition and a preparation method thereof. The rosuvastatin calcium oral drug composition is characterized by comprising the following components in proportion: 10-80mg of rosuvastatin calcium, 20-160mg of hydroxypropyl betadex, 5-40mg of meglumine, 2-16mg of sodium sulfite, 100-800mg of lactose, 50-400mg of microcrystalline cellulose, 20-160mg of croscarmellose sodium, 2-16mg of magnesium stearate and a proper amount of 80 percent ethanol solution. The preparation method comprises the following steps of: dissolving hydroxypropyl betadex, meglumine and magnesium stearate into a proper amount of 80% ethanol solution; adding rosuvastatin calcium and mixing until the rosuvastatin calcium is completely dissolved; evenly mixing lactose, microcrystalline cellulose and croscarmellose sodium for later use; quantitatively adding the solution into an evenly-mixed accessory for pelletization; and obtaining a finished product by drying, palletizing, totally mixing, checking an intermediate body, pressing into pieces, coating and packing. The prepared rosuvastatin calcium tablet has good stability and high bioavailability.

Stabilized pharmaceutical solid composition of ACE inhibitor comprising an ACE inhibitor and a selective dosage formulation thereof comprising of meglumine. The ACE inhibitor selectively combined with a dosage form including essentially the meglumine is surprisingly found to avoid the degradation of ACE inhibitor by such dosage forms especially the commonly used pharmaceutical excepients. In particular, the presence of the meglumine in the dosage form for the active along with the active ACE inhibitor surprisingly avoid the degradation of the ACE inhibitor due to a) cyclization via internal nucleophilic attack to form substituted diketopiperazines, b) hydrolysis of the side chain ester group, and c) oxidation to form products having often unwanted coloration.

The invention relates to an adenosine monophosphate meglumine injection and a preparation method thereof. The preparation process is to take an appropriate amount of water for injection, add sodium chloride, cyclic adenosine monophosphate, and meglumine, stir to dissolve completely, add 0.05-0.2% (W/V) activated carbon for needles by volume, and stir for 15-30 minutes. Filter to remove carbon, add water for injection to nearly full amount, use phosphate buffer to adjust the pH value to between 6.0 and 6.5, add water for injection to the full amount, and check that the semi-finished product is qualified, filter, potting (full nitrogen gas in the whole process), and extinguish Bacteria, light inspection, packaging. The method has the advantages of selecting appropriate solvents and additives, improving the solubility and stability of meglumine cyclic adenosine monophosphate, and adopting a terminal sterilization preparation method to effectively ensure the sterility assurance level of the drug. The invention has the characteristics of formula composition, simple process, low production cost, strong drug stability and safety, and the like.

The invention discloses dexibuprofen injection and a preparation method thereof. The invention is characterized in that the injection is preparation which is prepared by using dexibuprofen as the main ingredient. The preparation consists of dexibuprofen, meglumine, citric acid and trisodium citrate. The pH value of the solution is 5.0 to 7.0. The preparation has the advantages that: dexibuprofen acts quickly and is absorbed quickly; the medicinal liquid directly enters blood circulation without being affected by the digestion system and foods; and the like. The stability of the injection is high.

The invention provides a method for synthesizing flunixin meglumine. According to the method, reaction is carried out in a manner that 2-chloronicotinic acid and 2-methyl-3-trifluoromethylaniline serve as raw materials, water serves as a solvent and cupric oxide and para-toluenesulfonic acid serve as catalysts. According to the method, on the premise that the condition that para-toluenesulfonic acid serves as a catalyst is reported in the existing literature, cupric oxide is added, so that the catalysis efficiency is increased greatly, the reaction can be carried out efficiently, the reaction time is shortened, and the yield is increased; obtained flunixin and meglumine are salified in an acetonitrile solvent and are recrystallized, so as to obtain flunixin meglumine, and the total yield is about 90%; through synthesizing flunixin meglumine by the method, the operation is convenient and simple, and the requirements for equipment are low, so that the method is applicable to industrial large-scale production.